3 Active Ingredients and Custom Synthesis Leader, Branded Generics Innovator and Portable Molecular Testing Company Stocks With a Strong Future Roadmap: Divi’s Laboratories, Glenmark Pharmaceuticals and Molbio Diagnostics
- October 26, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Divi’s Laboratories, Glenmark Pharmaceuticals and Molbio Diagnostics: ROE of 14.2% to 28.1% and FY22 to FY26 revenue CAGR of 5.1% to 16.8%. Prices as of 23 Oct 2026.
Quick Answer
The three API, branded generics and Truenat testing stocks to watch are Divi’s Laboratories, Glenmark Pharmaceuticals and Molbio Diagnostics. Their return on equity ranges from 14.2% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 16.8%. Glenmark Pharmaceuticals has the highest return on equity at 28.1%, while Molbio Diagnostics has the fastest revenue growth at 16.8% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.
API, branded generics and Truenat testing stocks offer a focused view of a sector where demand keeps widening. Divi’s Laboratories, Glenmark Pharmaceuticals and Molbio Diagnostics cover an active ingredients and custom synthesis leader, a branded generics innovator and a portable molecular testing company.
This list covers three API, branded generics and Truenat testing stocks with complete current figures: Divi’s Laboratories, Glenmark Pharmaceuticals and Molbio Diagnostics. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are API, Branded Generics and Truenat Testing Stocks?
API, branded generics and Truenat testing stocks are listed healthcare companies that make active ingredients, branded medicines and portable disease tests. Their earnings depend on global orders, product launches, approvals and testing demand.
API, Branded Generics and Truenat Testing Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Divi’s Laboratories | 8,950 | 241,311 | 82.5 | 36.0 | 15.3 | 0.00 |
| Glenmark Pharmaceuticals | 2,166.6 | 60,103 | 33.4 | 35.7 | 28.1 | 0.06 |
| Molbio Diagnostics | 1,239.1 | 16,605 | 101.2 | 59.6 | 14.2 | 0.38 |
On valuation, Glenmark Pharmaceuticals trades at a P/E below the industry P/E, while Divi’s Laboratories and Molbio Diagnostics trade above it, which reflects the growth the market already expects. Readers comparing API, branded generics and Truenat testing stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do API, Branded Generics and Truenat Testing Stocks Have a Strong Roadmap in India?
API, branded generics and Truenat testing stocks have a strong roadmap in India because global buyers add dependable ingredient suppliers, branded medicines keep gaining reach and portable testing widens access to diagnosis.
- Custom synthesis. Global drug makers outsource complex molecules.
- Branded medicines. Research led launches widen markets.
- Point of care tests. Portable devices reach remote areas.
Why Divi’s Laboratories Features Among These API, Branded Generics and Truenat Testing Stocks
Among the API, branded generics and Truenat testing stocks on this list, Divi’s Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.
In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%.
Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0.
Roadmap: The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.
What to watch: Check the order flow in custom synthesis and the commissioning of new capacity.
Why Glenmark Pharmaceuticals Features Among These API, Branded Generics and Truenat Testing Stocks
Among the custom synthesis ingredient shares on this list, Glenmark Pharmaceuticals is a research-driven pharma company with branded generics in India and other emerging markets, generics in the United States and Europe, and an innovation arm focused on new drugs.
The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7.
Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore.
Roadmap: The company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.
What to watch: Track new product launches, progress in the innovation pipeline and balance sheet strength.
Why Molbio Diagnostics Features Among These API, Branded Generics and Truenat Testing Stocks
Among the three companies on this list, Molbio Diagnostics, based in Goa, develops the Truenat platform, a portable molecular diagnostics system that delivers lab-grade PCR results at the point of care, with strong use in tuberculosis testing.
Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%.
The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6.
Roadmap: Its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What to watch: Order timing from public health programmes can be lumpy, so look at annual rather than single-quarter trends.
Divi’s Laboratories vs Glenmark Pharmaceuticals vs Molbio Diagnostics on Key Financials
The table below sets the three API, branded generics and Truenat testing stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Divi’s Laboratories | 9,074 | 11,067 | 5.1% | 2,568 | 23.2% |
| Glenmark Pharmaceuticals | 12,472 | 17,443 | 8.7% | 1,362 | 7.8% |
| Molbio Diagnostics | 782 | 1,455 | 16.8% | 164 | 11.3% |
Glenmark Pharmaceuticals posts the highest return on equity in this group at 28.1%. Glenmark Pharmaceuticals has the largest FY26 revenue at Rs 17,443 crore, and Molbio Diagnostics shows the fastest revenue growth with a 16.8% compound annual rate. A useful habit with API, branded generics and Truenat testing stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in API, Branded Generics and Truenat Testing Stocks
Every theme carries risks that deserve a check before any decision. For these API, branded generics and Truenat testing stocks, the main points are: Long-term custom synthesis ingredient shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory checks. Plant inspections can affect approvals.
- Order timing. Large contracts can shift between periods.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter API, branded generics and Truenat testing stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on API, Branded Generics and Truenat Testing Stocks
API, branded generics and Truenat testing stocks reward patient research into demand, execution and financial strength. Divi’s Laboratories, Glenmark Pharmaceuticals and Molbio Diagnostics each have a clear plan to grow. Based on the 23 October 2026 close, Divi’s Laboratories trades at Rs 8,950, Glenmark Pharmaceuticals at Rs 2,166.6 and Molbio Diagnostics at Rs 1,239.1.
Download the Univest iOS App or Univest Android App to track API, branded generics and Truenat testing stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are API, branded generics and Truenat testing stocks?
Ans. API, branded generics and Truenat testing stocks are listed healthcare companies that make active ingredients, branded medicines and portable disease tests. Their earnings depend on global orders, product launches, approvals and testing demand. This list looks at three of them, Divi’s Laboratories, Glenmark Pharmaceuticals and Molbio Diagnostics, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.
Which API, branded generics and Truenat testing stocks are covered in this list?
Ans. This list covers Divi’s Laboratories, Glenmark Pharmaceuticals and Molbio Diagnostics. Based on the 23 October 2026 close, Divi’s Laboratories traded at Rs 8,950, Glenmark Pharmaceuticals at Rs 2,166.6 and Molbio Diagnostics at Rs 1,239.1. Their return on equity ranges from 14.2% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 16.8%.
Why do API, branded generics and Truenat testing stocks have a strong future roadmap in India?
Ans. API, branded generics and Truenat testing stocks have a strong roadmap in India because global buyers add dependable ingredient suppliers, branded medicines keep gaining reach and portable testing widens access to diagnosis. The main drivers are as follows. Custom synthesis. Global drug makers outsource complex molecules. Branded medicines. Research led launches widen markets. Point of care tests. Portable devices reach remote areas. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Divi’s Laboratories performed financially?
Ans. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.
How has Glenmark Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.
How has Molbio Diagnostics performed financially?
Ans. Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What risks should investors check before buying API, branded generics and Truenat testing stocks?
Ans. Investors should check a few risks before buying API, branded generics and Truenat testing stocks. Regulatory checks. Plant inspections can affect approvals. Order timing. Large contracts can shift between periods. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of API, branded generics and Truenat testing stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.